Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Blakney AK, Jiang Y, Whittington D, Woodrow KA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jul 1;1025:110-8. doi: 10.1016/j.jchromb.2016.04.048. Epub 2016 May 2.

2.

Maraviroc: a review of its use in HIV infection and beyond.

Woollard SM, Kanmogne GD.

Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015. Review.

3.

Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.

Van Der Ryst E.

Front Immunol. 2015 Jun 5;6:277. doi: 10.3389/fimmu.2015.00277. eCollection 2015. Review. No abstract available.

4.

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Lu Y, Fuchs EJ, Hendrix CW, Bumpus NN.

Drug Metab Dispos. 2014 Nov;42(11):1796-802. doi: 10.1124/dmd.114.060194. Epub 2014 Aug 12.

5.

HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba AD, Akkina R.

Virology. 2014 Sep;464-465:253-63. doi: 10.1016/j.virol.2014.07.008. Epub 2014 Aug 7.

6.
7.

The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.

Maguire JJ, Jones KL, Kuc RE, Clarke MC, Bennett MR, Davenport AP.

Cardiovasc Res. 2014 Mar 1;101(3):513-21. doi: 10.1093/cvr/cvt333. Epub 2013 Dec 9.

8.

Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6158-64. doi: 10.1128/AAC.01098-13. Epub 2013 Sep 30.

9.

Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc.

Lu Y, Hendrix CW, Bumpus NN.

Drug Metab Dispos. 2012 Dec;40(12):2221-30. doi: 10.1124/dmd.112.048298. Epub 2012 Aug 24.

10.
11.

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG.

Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685.

12.

Switching antiretroviral therapy to minimize metabolic complications.

Lake JE, Currier JS.

HIV Ther. 2010 Nov;4(6):693-711.

13.

Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Rudek MA, Flexner C, Ambinder RF.

Lancet Oncol. 2011 Sep;12(9):905-12. doi: 10.1016/S1470-2045(11)70056-0. Epub 2011 May 12. Review.

14.

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, Kashuba AD.

J Infect Dis. 2011 May 15;203(10):1484-90. doi: 10.1093/infdis/jir059.

15.

Hypersensitivity reactions to HIV therapy.

Chaponda M, Pirmohamed M.

Br J Clin Pharmacol. 2011 May;71(5):659-71. doi: 10.1111/j.1365-2125.2010.03784.x. Review.

16.

Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.

Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM.

Antimicrob Agents Chemother. 2011 May;55(5):2290-6. doi: 10.1128/AAC.01046-10. Epub 2011 Mar 7.

17.

Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.

Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M.

Antimicrob Agents Chemother. 2010 Oct;54(10):4059-63. doi: 10.1128/AAC.00747-10. Epub 2010 Aug 9.

18.

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.

Andrews E, Glue P, Fang J, Crownover P, Tressler R, Damle B.

Br J Clin Pharmacol. 2010 Jan;69(1):51-7. doi: 10.1111/j.1365-2125.2009.03546.x.

19.

Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.

Weatherley B, McFadyen L.

Br J Clin Pharmacol. 2009 Sep;68(3):355-69. doi: 10.1111/j.1365-2125.2009.03455.x.

20.

Drug interactions with new and investigational antiretrovirals.

Brown KC, Paul S, Kashuba AD.

Clin Pharmacokinet. 2009;48(4):211-41. doi: 10.2165/00003088-200948040-00001. Review.

Supplemental Content

Support Center